Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.50 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)1.23M
Market Cap
$434.59M
Enterprise Value$22.45
Total Cash (Recent Filing)$191.48M
Total Debt (Recent Filing)$22.93M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 11, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend Yield1.29%
Share Statistics
EPS (TTM)-3.33
Shares Outstanding28,423,069
10 Day Avg. Volume883,768
30 Day Avg. Volume1,225,769
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.33Price Target Upside141.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.45
Revenue Forecast (FY)$18.64M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Funded RunwayModest leverage limits borrowing-related financial risk, while the stated cash runway supports continued clinical and regulatory work through major upcoming milestones. This provides time to advance the pipeline and pursue partnering or commercialization without immediate dependence on debt financing.
Validated Sa-mRNA Platform And Vaccine RightsRegaining global rights restores control over a platform described as validated and already approved across more than 30 countries. Commercial-ready manufacturing and lower dose requirements could support future partnering, geographic expansion, and more direct monetization.
Pipeline Progress And Strategic SupportProgress across rare-disease programs creates several potential value inflection points rather than reliance on one candidate. Thermo Fisher’s manufacturing support could improve execution capacity if ARCT-032 advances, strengthening the path toward late-stage development.
Bears Say
Persistent Losses And Cash BurnOngoing operating and free-cash-flow deficits show that current activities consume substantial cash and are not yet self-funding. Deep net losses can erode the asset base over time, making successful clinical progress, partnering, or future commercialization important to preserve financial flexibility.
Severe Revenue Contraction After CSL Wind-downThe sharp decline demonstrates that reported revenue remains highly dependent on collaboration activity rather than a stable recurring base. With CSL revenue largely ended, Arcturus must replace that contribution through new partnerships, milestones, royalties, or successful direct commercialization.
Key Programs Remain Clinically And Regulatorily UncertainImportant pipeline assets still depend on upcoming efficacy data and regulatory review, so current progress has not yet established late-stage or commercial success. Delays or unfavorable outcomes could weaken partnering prospects and prolong the period of losses and cash consumption.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.50 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $434.59M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 56 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.996 by $0.156.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of 1.29%. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.996. Following the earnings report the stock price went up 21.875%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.33 (141.05% Upside)
$21.33 (141.05% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 75%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 132.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
ARCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of strategic, clinical, and financial developments. Positive operational milestones include completed enrollment for ARCT-810, continued ARCT-032 Phase II progress with international expansion, regained global rights to a validated sa-mRNA vaccine platform (KOSTAIVE) along with a $12M settlement, a Thermo Fisher manufacturing collaboration for CF, and a completed Phase I pandemic flu study with BARDA support and an accepted manuscript. Offsetting these positives are material near-term financial headwinds: revenue declined sharply year-over-year (~-89% quarter, ~-91% six months) as the CSL collaboration wound down, cash declined by ~17% in H1 2026, and Arcturus now bears the responsibility to commercialize or partner its vaccine portfolio. R&D spending decreased materially (~-40%) and G&A saw modest increases due to legal fees. Overall, strategic and clinical advances are meaningful but are balanced by significant revenue and cash impacts that require successful commercialization/partnering and upcoming data readouts to validate the company’s runway and prospects.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$21.33
▲(141.05% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
7.26%
Insiders
23.74% Mutual Funds
31.09% Other Institutional Investors
15.95% Public Companies and
Individual Investors